SCHEMBL2690201

SCHEMBL2690201

NC(=O)c1ccc(-c2ccccc2)s1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 3/20 0.68
RAB9A P51151 3/20 0.67
MEN1 O00255 1/20 0.67
POLB P06746 1/20 0.67
KMT2A Q03164 1/20 0.67
HDAC1 Q13547 1/20 0.65
NPC1 O15118 2/20 0.61
KDM4E B2RXH2 1/20 0.61
ALDH1A1 P00352 1/20 0.61
HPGD P15428 1/20 0.61
HDAC6 Q9UBN7 1/20 0.61
EPHX2 P34913 1/20 0.59
PPARG P37231 1/20 0.59
NCOA2 Q15596 1/20 0.59
NCOA1 Q15788 1/20 0.59
NCOA3 Q9Y6Q9 1/20 0.59
HPGDS O60760 2/20 0.58
ERCC5 P28715 1/20 0.57
FEN1 P39748 1/20 0.57
NQO2 P16083 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1784584 0.84 HPGDS (0.73) IKBKBEPHX2HPGDS
SCHEMBL6612574 0.84 HPGDS (0.60) IKBKBRAB9AMEN1POLBKMT2A
SCHEMBL27623980 0.83 RAB9A (0.71) RAB9AMEN1POLBKMT2AHDAC1
SCHEMBL1761545 0.83 RAB9A (0.92) RAB9AMEN1POLBKMT2AHDAC1
SCHEMBL28541614 0.83 EPHX2 (0.58) IKBKBRAB9AMEN1POLBKMT2A
SCHEMBL27565420 0.83 ESRRG (0.59) IKBKBHDAC6EPHX2HPGDSTP53
SCHEMBL27565581 0.83 IKBKB (0.71) IKBKBRAB9AMEN1POLBKMT2A
SCHEMBL29922717 0.83 EPHX2 (0.58) IKBKBRAB9AMEN1POLBKMT2A
SCHEMBL10275320 0.82 RAB9A (0.69) RAB9AMEN1POLBKMT2AHDAC1
SCHEMBL6378947 0.81 IKBKB (1.00) IKBKBRAB9AMEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1400973-A Novel biarylcarboxamides ASTRAZENECA AB (SE) 2003-03-05 CN claimed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2023233024-A1 DPP9 BINDING COMPOUNDS UNIVERSITEIT ANTWERPEN (BE) 2023-12-07 WO disclosed
EP-3274341-B1 INHIBITORS OF PSEUDOMONAS AERUGINOSA LECB HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) 2022-11-02 EP disclosed
CN-107531686-B Inhibitors of pseudomonas aeruginosa LecB 亥姆霍兹感染研究中心有限责任公司 2021-07-09 CN disclosed
US-10407398-B2 Inhibitors of Pseudomonas aeruginosa LecB Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2019-09-10 US disclosed
US-20180155310-A1 INHIBITORS OF PSEUDOMONAS AERUGINOSA LECB Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2018-06-07 US disclosed
EP-3045457-B1 SUBSTITUTED PYRIMIDINYLPYRROLOPYRIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2018-05-09 EP disclosed
EP-3274341-A1 INHIBITORS OF PSEUDOMONAS AERUGINOSA LECB Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2018-01-31 EP disclosed
CN-107531686-A Pseudomonas aeruginosa LecB inhibitor 亥姆霍兹感染研究中心有限责任公司 2018-01-02 CN disclosed
US-8546413-B2 Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-10-01 US disclosed
US-20120178770-A1 SUBSTITUTED PYRIMIDINYLPYRROLOPYRIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-07-12 US disclosed
US-20120107273-A1 NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-05-03 US disclosed
CN-102256969-A Compounds that modulate intracellular calcium CALCIMEDICA INC 2011-11-23 CN disclosed
WO-2009102325-A1 IMIDAZOLYL BIPHENYL IMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-20 WO disclosed
EP-2009004-A1 NOVEL PIPERAZINE COMPOUND, AND USE THEREOF AS HCV POLYMERASE INHIBITOR Japan Tobacco, Inc. (JP) 2008-12-31 EP disclosed
US-20080081818-A1 therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors JAPAN TOBACCO INC. (JP) 2008-04-03 US disclosed
WO-2008021927-A2 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-02-21 WO disclosed
CN-100345847-C Novel biarylcarboxamides ASTRAZENECA AB (SE) 2007-10-31 CN disclosed
CN-1400973-A Novel biarylcarboxamides ASTRAZENECA AB (SE) 2003-03-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081818-A1 therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors HAVCR2, AADAC, DNPEP IKBKB 173/4885RAB9A 4538/4885MEN1 4883/4885
US-20180155310-A1 INHIBITORS OF PSEUDOMONAS AERUGINOSA LECB FUCA1, ALG1, FUCA2 IKBKB 735/4885RAB9A 1973/4885MEN1 4081/4885
US-10407398-B2 Inhibitors of Pseudomonas aeruginosa LecB FUCA1, ALG1, FUCA2 IKBKB 735/4885RAB9A 1973/4885MEN1 4081/4885
US-20120107273-A1 NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR POLR1C, POLR2E, POLR2H IKBKB 513/4885RAB9A 3868/4885MEN1 4872/4885
US-20120178770-A1 SUBSTITUTED PYRIMIDINYLPYRROLOPYRIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS MAP3K5, MAP3K9, MAP3K1 IKBKB 421/4885RAB9A 1307/4885MEN1 2345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.